Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indapamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 1.00 |
| ▸ | CA2 | P00918 | 10/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA6 | P23280 | 3/20 | 1.00 |
| ▸ | CA5A | P35218 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indapamide SCHEMBL41303 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL29372690 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL2329030 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL29377544 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL163266 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL29496872 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL2989867 | 0.99 | CA1 (0.98) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL3159715 | 0.99 | CA1 (0.98) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL28261247 | 0.96 | CA1 (0.92) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL16180488 | 0.94 | CA1 (0.89) | CA1CA2CA12CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411006-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | Gupta, Ajay (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111599-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | GUPTA AJAY (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7544711-B2 | Use of nitroderivatives in urinary incontinence | NICOX S.A. (FR) | 2009-06-09 | — | — | US | disclosed |
| US-20050101661-A1 | Use of nitroderivatives in urinary incontinence | NICOX S.A. (FR) | 2005-05-12 | — | — | US | disclosed |
| EP-1473288-A1 | Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases | Nicox S.A. (FR) | 2004-11-03 | — | — | EP | disclosed |
| EP-1437132-A1 | Use of nitric ester derivatives in the manufacture of a medicament for the treatment of gastrointestinal tumors | Nicox S.A (FR) | 2004-07-14 | — | — | EP | disclosed |
| US-20040082652-A1 | Nitric ester derivatives and their use in treating gastrointestinal tumors | NICOX S.A. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082652-A1 | Nitric ester derivatives and their use in treating gastrointestinal tumors | NOS1, PTGER1, NOS3 | CA1 903/4885CA2 1001/4885CA12 2065/4885 |
| US-20050101661-A1 | Use of nitroderivatives in urinary incontinence | NR0B1, NOX1, AKR1C1 | CA1 2187/4885CA2 2238/4885CA12 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.